… filing for a potential April IPO at a valuation that … #39;s more conservative expected IPO valuation of $3 billion, … Blue Shield agreements, expanded its GLP-1 weight management solution targeting … numbers relating to HingeHealth’s IPO are based on publicly …

… developments matter, read on. Semaglutide GLP-1 Shortage Over, But ‘ … , the active ingredient in GLP-1 drugs Wegovy and Ozempic … , the active ingredient in GLP-1 drugs Mounjaro and Zepbound … a dizzying pace. An IPO filing from tech-enabled provider …

… listed company prior to its initial public offering filing with the Nasdaq Global … plays in the diets of GLP-1 users. “What we see … is that people who use GLP-1s are staying with a …

… address SYNGAP1-related disorders; GLP toxicology studies expected to … designations, and completing our initial public offering,” said Josh Mandel-Brehm, … expected in Q4 2025. GLP toxicity studies of CMP- … company’s initiation of GLP toxicity studies relating to …

… the pricing of its initial public offering of 5,888, … limitations of currently marketed GLP-1 therapies for … anticipated size of the initial public offering and the expected … to the initial public offering, the completion of the initial public offering on the …

… to focus solely on its GLP-1-delivering implant technologies. Our … to continue advancing its miniature GLP-1 therapeutic implants. The spin … S-1 to support an IPO for Cortigent. It revised its …

Digital chronic disease management platform Health2Sync has recently raised $20 million in a Series C funding round led by Taiwania Capital. Wistron, Pegatron, BE Health Ventures, ABIES Capital, and Cathay Venture also joined the round. This latest …

… potent, subcutaneously injectable GLP-1 receptor agonist ( … Recent Business Highlights Completed initial public offering (IPO) In February, Metsera … prepared for our initial public offering and an increase … prospectus for our initial public offering and in our …

… $94.2m in an initial public offering (IPO) to support the development … like peptide 1 receptor agonist (GLP-1RA) drugs like  Zepbound … Pharma. Market sentiment around IPOs has shown a sign of … surveyed healthcare investors expected IPOs and equity raises to …

… speculation with a $94 million initial public offering, putting itself on the … initially filed plans for its IPO in late January without … different biochemical pathways than the GLP-1 agonists Wegovy and … dominating the market. The IPO comes after an $85 …